α-SMA is one of the markers that monitors liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) (Di Cerbo et al., 2016; Patel et al., 2020). This evidence concerns the gene ACTA1 and metabolic dysfunction-associated steatotic liver disease.